P04.03 GLIOMA SPECIFIC TARGET IDENTIFICATION WITH APTAMERS

DESIGN: Aptamers are in vitro generated, short DNA and RNA sequences which are randomly created as a library. They are created with multiple permutations and combinations automatically within set primer ends. These are then exposed to the target structure against which we want an aptamer 'selec...

Full description

Saved in:
Bibliographic Details
Published inNeuro-oncology (Charlottesville, Va.) Vol. 16; no. suppl 2; p. ii37
Main Author Arora, M.
Format Journal Article
LanguageEnglish
Published 01.09.2014
Online AccessGet full text

Cover

Loading…
Abstract DESIGN: Aptamers are in vitro generated, short DNA and RNA sequences which are randomly created as a library. They are created with multiple permutations and combinations automatically within set primer ends. These are then exposed to the target structure against which we want an aptamer 'selected', using Sequential Enumeration of Ligands by Exponential enrichment (SELEX). Modified aptamers based on published sequences against glioma cell lines and newly generated sequences were used in the project to identify their binding targets. SUBJECTS: Commercially available glioma and glial cell lines were used along with in-house generated primary glioma cultures. METHODS: Cy3 and biotin- conjugated aptamers were incubated with live glioma cell cultures and imaged using confocal or light microscopy. This established proof of concept that the aptamers were binding to the glial cell more specifically than control. To determine the target ligand, aptamers were then reacted with glial cell lysate and subjected to precipitation using streptavidin agarose beads and SDS polyacrylamide gel electrophoresis. Proteins were then analysed by mass spectroscopy. RESULTS: Known and unknown aptamer protein ligands were co-precipitated. X ray cross complementing protein 6 (XRCC6 or Ku70) and x ray cross complementing protein 5 (XRCC5 or Ku80) were precipitated along with nucleolin and other related proteins. Heterogenous nuclear ribonuclear proteins or hnRNP's were also isolated. Ku70 and Ku80 were also precipitated in primary cell cultures. KU70 and Ku80 appear in the KEGG pathway and Non-homologus end joining pathway or NHEJ for DNA repair. CONCLUSIONS: The aptamer has shown preferential binding to glioma cells and could act as a delivery system for therapeutic payloads. The aptamer targets Ku70 and Ku80, which are known to be over expressed in other forms of cancer but their role in gliomagenesis has not been fully elucidated. Other novel proteins have also been identified. Thus the aptamer co-precipitation technique has identified potential glioma biomarkers that may be of clinical significance.
AbstractList DESIGN: Aptamers are in vitro generated, short DNA and RNA sequences which are randomly created as a library. They are created with multiple permutations and combinations automatically within set primer ends. These are then exposed to the target structure against which we want an aptamer 'selected', using Sequential Enumeration of Ligands by Exponential enrichment (SELEX). Modified aptamers based on published sequences against glioma cell lines and newly generated sequences were used in the project to identify their binding targets. SUBJECTS: Commercially available glioma and glial cell lines were used along with in-house generated primary glioma cultures. METHODS: Cy3 and biotin- conjugated aptamers were incubated with live glioma cell cultures and imaged using confocal or light microscopy. This established proof of concept that the aptamers were binding to the glial cell more specifically than control. To determine the target ligand, aptamers were then reacted with glial cell lysate and subjected to precipitation using streptavidin agarose beads and SDS polyacrylamide gel electrophoresis. Proteins were then analysed by mass spectroscopy. RESULTS: Known and unknown aptamer protein ligands were co-precipitated. X ray cross complementing protein 6 (XRCC6 or Ku70) and x ray cross complementing protein 5 (XRCC5 or Ku80) were precipitated along with nucleolin and other related proteins. Heterogenous nuclear ribonuclear proteins or hnRNP's were also isolated. Ku70 and Ku80 were also precipitated in primary cell cultures. KU70 and Ku80 appear in the KEGG pathway and Non-homologus end joining pathway or NHEJ for DNA repair. CONCLUSIONS: The aptamer has shown preferential binding to glioma cells and could act as a delivery system for therapeutic payloads. The aptamer targets Ku70 and Ku80, which are known to be over expressed in other forms of cancer but their role in gliomagenesis has not been fully elucidated. Other novel proteins have also been identified. Thus the aptamer co-precipitation technique has identified potential glioma biomarkers that may be of clinical significance.
Author Arora, M.
Author_xml – sequence: 1
  givenname: M.
  surname: Arora
  fullname: Arora, M.
BookMark eNotkD1vwjAYhK2KSgXaH9AtY5eAXzt27G4RDRCJL4GrjpbjvkhUkNC4Gfj3habTnU53NzwD0qvqCgl5BjoCqvm4wrau_LiqW0iTEXBxR_ogGI-FkrL351msBKQPZBDCF6UMhIQ-ed3QZER5NFsU62UW7Tb5pJgWk8hk21luouItX5lbkJlivYo-CjOPso3Jlvl290ju9-4Y8Olfh-R9mpvJPF6sZ9fBIvYASsQ-RemwZBRSdAmyPfhSJy6l6FKnOZdOlwwZlkJ5hcg_EUrlmXAuEVonwIfkpfs9N_V3i-HHng7B4_HoKqzbYEFRJRlIrq9V6Kq-qUNocG_PzeHkmosFam-cbMfJdpzslRP_BauLWfM
ContentType Journal Article
DBID AAYXX
CITATION
7QO
7TK
8FD
FR3
P64
DOI 10.1093/neuonc/nou174.135
DatabaseName CrossRef
Biotechnology Research Abstracts
Neurosciences Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitle CrossRef
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
DatabaseTitleList Engineering Research Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1523-5866
EndPage ii37
ExternalDocumentID 10_1093_neuonc_nou174_135
GroupedDBID ---
.2P
.I3
.XZ
.ZR
0R~
123
18M
1TH
2WC
36B
4.4
48X
53G
5VS
5WD
70D
AABZA
AACZT
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAVAP
AAYXX
ABEUO
ABIXL
ABJNI
ABKDP
ABNHQ
ABNKS
ABPTD
ABQLI
ABQNK
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACUFI
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFXAL
AFXEN
AGINJ
AGKEF
AGQXC
AGSYK
AGUTN
AHXPO
AIAGR
AIJHB
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AOIJS
APIBT
APWMN
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CITATION
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EJD
EMB
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HYE
HZ~
IOX
J21
KBUDW
KOP
KQ8
KSI
KSN
M49
MHKGH
N9A
NGC
NOMLY
NOYVH
NU-
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
P6G
PAFKI
PEELM
Q1.
Q5Y
RD5
RHF
ROX
RPM
RUSNO
RW1
RXO
SV3
TEORI
TJX
TR2
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
~91
7QO
7TK
8FD
FR3
P64
ID FETCH-LOGICAL-c1185-c7e6aeb2017ea4e2f1cb94a70ea7a9336a9b2e2eb58c8ee3de1b8c25aa4599413
ISSN 1522-8517
IngestDate Fri Oct 25 11:56:37 EDT 2024
Fri Aug 23 02:51:36 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue suppl 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1185-c7e6aeb2017ea4e2f1cb94a70ea7a9336a9b2e2eb58c8ee3de1b8c25aa4599413
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/neuro-oncology/article-pdf/16/suppl_2/ii37/3614712/nou174.135.pdf
PQID 1808621639
PQPubID 23462
ParticipantIDs proquest_miscellaneous_1808621639
crossref_primary_10_1093_neuonc_nou174_135
PublicationCentury 2000
PublicationDate 2014-09-01
20140901
PublicationDateYYYYMMDD 2014-09-01
PublicationDate_xml – month: 09
  year: 2014
  text: 2014-09-01
  day: 01
PublicationDecade 2010
PublicationTitle Neuro-oncology (Charlottesville, Va.)
PublicationYear 2014
SSID ssj0021561
Score 2.1098902
Snippet DESIGN: Aptamers are in vitro generated, short DNA and RNA sequences which are randomly created as a library. They are created with multiple permutations and...
SourceID proquest
crossref
SourceType Aggregation Database
StartPage ii37
Title P04.03 GLIOMA SPECIFIC TARGET IDENTIFICATION WITH APTAMERS
URI https://search.proquest.com/docview/1808621639
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSIgLojxEW0BB4kSUtnk65rYq2W5gd7uiWbE3y3YmUi8Jand76K_vTJzsQ-VQuESJFSXWfMn4G8-LsS86NQptWcpY5qUX8VJ4WgP3qoqXEYS4wqeU4DyZJqN59GMRLzb9MdvskqU-Nnd_zSv5H1RxDHGlLNl_QHb9UBzAc8QXj4gwHh-F8YzKp4bu-Ti_mAzcy1l2lg9zCsT7dZ4Vbv49mxY0YDvr_M6LkTuYFVQJ4XKbk7b1ObymNrYcE7l1yQffLJGF3lKqYBsLq463Nw2um7Y_UbeX2u0a-NE6LGqt6NAIRbbFdzRhsoX4DXUVdYMt5XZ1ZeuzdAtlf_lACdsCVTWscOZ00qzQ7KEGG5s1p_ezTy_kcD4eyyJbFE_Zs4Cq9RGzzX-urWY0MG3R227CvWtahCf2FSebF-ySi921tSUMxSv2smP6zsDCts-eQP2aPZ90sQxv2DeLnmPRc3r0HIues4ueQ-g5PXpv2XyYFWcjr-tk4Rk04GLPcEgUaASCg4ogqHyjRaT4KSiuRBgmSugAAtBxalKAsAQff6IgViqKhUCe8Y7t1U0N75kDvm_QxjutUh-iRCkRB6FKhClxUCS6OmBfexHIP7ZgibSBBqG08pJWXhLldcA-90KSqFbIV6RqaFY30k_J1kWyLg4fcc8Re7H5yD6wveX1Cj4iWVvqTy2Y92AoNhQ
link.rule.ids 315,783,787,27937,27938
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=P04.03+GLIOMA+SPECIFIC+TARGET+IDENTIFICATION+WITH+APTAMERS&rft.jtitle=Neuro-oncology+%28Charlottesville%2C+Va.%29&rft.au=Arora%2C+M&rft.date=2014-09-01&rft.issn=1522-8517&rft.volume=16&rft.issue=suppl+2&rft.spage=ii37&rft.epage=ii37&rft_id=info:doi/10.1093%2Fneuonc%2Fnou174.135&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-8517&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-8517&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-8517&client=summon